What is HC Wainwright’s Estimate for RNAZ FY2024 Earnings?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Equities researchers at HC Wainwright lifted their FY2024 earnings per share estimates for shares of TransCode Therapeutics in a note issued to investors on Wednesday, December 18th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($4.76) for the year, up from their previous forecast of ($60.73). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($3.21) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.62) EPS.

TransCode Therapeutics Stock Down 4.8 %

Shares of RNAZ stock opened at $3.58 on Monday. TransCode Therapeutics has a 52 week low of $3.21 and a 52 week high of $264.00. The stock has a fifty day moving average of $380.38 and a 200 day moving average of $542.28.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management grew its holdings in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.